Peptide News Digest

#50-Copay

2 stories

Regulatory · View digest

TrumpRx GLP-1 Pricing Rollout: $245 Zepbound and Wegovy Medicare Coverage Plus TrumpRx Direct-to-Consumer Portal Launch on Schedule for January 2026

The Trump administration's landmark November 6, 2025 GLP-1 drug pricing agreement with Eli Lilly and Novo Nordisk continues implementation through September 2026 with the TrumpRx.gov direct-to-consumer platform on schedule for January 2026 launch. Terms confirmed as of September 1, 2026: starting doses of Wegovy and Zepbound available at $350/month on TrumpRx (trending down to $245/month over a two-year period); Medicare prices set at $245/month for Ozempic, Wegovy, Mounjaro, and Zepbound, with Medicare beneficiaries paying $50/month copays; upcoming oral obesity pills (Lilly Foundayo, Novo Wegovy pill) priced at $149/month for Medicare, Medicaid, and TrumpRx patients. The Most-Favored-Nation pricing framework requires both companies to guarantee MFN prices on all new medications and repatriate increased foreign revenue on existing products. The agreement extends Medicare coverage to Wegovy and Zepbound for obesity plus related comorbidities for the first time, ending the Medicare Part D exclusion that has constrained the class since launch.

Industry · View digest

Medicare GLP-1 Bridge Program Marks 27 Days Since the July 1, 2026 CMS Pilot Launch That Provides All Formulations of Wegovy (Semaglutide, Novo Nordisk), the KwikPen Formulation of Zepbound (Tirzepatide, Eli Lilly), and All Formulations of Foundayo (Orforglipron, Eli Lilly) at a Capped $50 Monthly Copay for Eligible Medicare Part D Beneficiaries Through December 31, 2027; KFF Analysis Estimates Approximately 3.8 Million Medicare Beneficiaries Meet the Clinical Eligibility Criteria for the Program (~8% of the 47.5 Million Part D Enrollees Nationally), Though CMS Has Not Yet Released Actual Enrollment Data From the First Program Month

The Centers for Medicare & Medicaid Services (CMS) Medicare GLP-1 Bridge Program is 27 days into the July 1, 2026 pilot launch. The program provides eligible Medicare Part D beneficiaries access to specified GLP-1 receptor agonist products at a capped $50 monthly out-of-pocket cost through December 31, 2027. Covered products include all formulations of Wegovy (semaglutide, Novo Nordisk), the KwikPen formulation of Zepbound (tirzepatide, Eli Lilly), and all formulations of Foundayo (orforglipron, Eli Lilly). The program was created through a Most-Favored-Nation (MFN) pricing agreement announced by the Trump administration in Q1 2026 that pairs manufacturer discounts with a fixed patient copay. A KFF (Kaiser Family Foundation) analysis estimates approximately 3.8 million Medicare beneficiaries meet the program's clinical eligibility criteria (obesity with BMI ≥ 30 kg/m² and specific cardiovascular or metabolic comorbidities), representing approximately 8% of the 47.5 million Part D enrollees nationally. CMS has not yet released actual enrollment data from the first program month. The program's actual utilization pattern, adherence rate, and expenditure trajectory will inform whether the pilot is extended past December 31, 2027 or converted to a permanent Medicare Part D obesity benefit.